SALUGGIA, Italy - CID is pleased to announce that its latest Drug Eluting Stent (DES), Cre8™, has received CE mark.

The Cre8TM polymer-free DES embodies the most advanced DES technologies to treat coronary vascular disease. Its unique distinctive features - Abluminal Reservoir Technology, Amphilimus Formulation and Bio Inducer Surface – make Cre8™ the only very effective Polymer-Free DES today available. In the NEXT study, an international prospective randomized clinical trial, it resulted being statistically superior to TAXUS™ Libertè with respect to in-stent late lumen loss (0.14 mm Cre8™ vs. 0.34 mm Taxus, p<0.0001).

The proprietary Abluminal Reservoir Technology (ART) provides a consistent drug loading onto the stent platform, thus enabling a controlled and directed elution exclusively targeted to the vessel wall.

The innovative Amphilimus™ formulation, that is Sirolimus formulated with an organic acid, is the first known use of a carrier to enhance drug bioavailability and drug distribution to the entire vessel wall.

The Bio Inducer Surface, a second generation integral pure carbon coating, demonstrates excellent results in terms of stent endothelialization and struts coverage. The use of the Bio Inducer Surface onto the Cre8TM Polymer-Free DES enables faster DES endothelialisation and reduces device thrombogenicity risk.

“We develop our stents with the objective of providing patients the best possible clinical outcome in terms of both efficacy and safety. We believe that Cre8TM represents an important achievement for the interventional cardiologist community, as it is a DES that has none of the drawbacks associated with polymers. In addition, because of the Bio Inducer Surface and Abluminal Reservoir Technology, we hope that physicians will be able to shorten the dual antiplatelet therapy period for their patients and reduce the high cost of care as well as the side effects of these drugs.” said Franco Vallana, President and C.E.O. of CID SpA.

Source: CID SpA